Evidence map›Paper›PMID 41142830›Full record

ArticleFrontiers in immunology2025

Leukocyte dynamics in

Gheorghe Braileanu, Agnes M Azimzadeh, Tianshu Zhang, Lars Burdorf, Richard N Pierson Iii

Erratum issuedAbstract read
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors.

Gheorghe Braileanu *Department of Surgery, University of Maryland Medical Center, Baltimore, MD, United States.
Agnes M Azimzadeh *Department of Surgery, University of Maryland Medical Center, Baltimore, MD, United States.
Tianshu ZhangDepartment of Surgery, University of Maryland Medical Center, Baltimore, MD, United States.
Lars BurdorfDepartment of Surgery, University of Maryland Medical Center, Baltimore, MD, United States.
Richard N Pierson Iii *Department of Surgery, University of Maryland Medical Center, Baltimore, MD, United States.

Funding

Project 3: Enhanced Costimulation Blockade to Achieve Clinically Relevant Heart Allograft ToleranceP01HL158504 · NHLBI · MASSACHUSETTS GENERAL HOSPITAL · PI MADSEN, JOREN C · 2021 to 2025
$12.1M
Immunomodulation for Heart Allograft ToleranceU01AI066719 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI PIERSON, RICHARD N · 2005 to 2016
$8.5M
NHLBI NIH HHS P01 HL158504NIAID NIH HHS U01 AI066719
6 · The paper itself

Abstract

Rationale: It was hypothesized that the dynamics of leukocyte populations in peripheral blood (PB) or peri-graft lymph nodes (LNs) in cynomolgus monkey recipients of a heterotopic heart allotransplant, completed with the determination of graft-infiltrating lymphocyte (GIL) populations at explant, may vary in association with immune rejection mechanisms or immunomodulatory treatments. Methods: Among 15 cynomolgus monkey recipients of heterotopic heart allografts, 13 were treated with a variety of costimulation-blocking immunosuppressive (IS) agents targeting CD80/CD86, CD28, CD40, or CD154, and two were untreated (controls). Leukocyte populations were characterized using hemocytometry and flow cytometry. Results: In PB, neutrophils and monocytes increased significantly (p < 0.001) during the first 2 weeks after transplant. Eosinophils and monocytes steadily increased after transplant, peaking around the time of graft failure (p < 0.01), a trend most prominent in association with belatacept. After the initial nadir on day 1 after transplant, PB lymphocytes increased steadily, particularly in association with belatacept and hu5c8, to a peak 1 week before graft rejection (p < 0.05), like CD3 cells. In PB, the CD4/CD8 ratio consistently trended down in all treated groups, most prominently in association with 5c8. In LNs at explant, CD4 cells outnumbered CD8 cells (p < 0.001), whereas in graft-infiltrating lymphocytes (GILs), CD8 cells predominated (p < 0.001). Among GILs at the time of rejection, CD8+CD62- central and effector memory cells were prominent, along with CD4+CD8+ T cells and IgD-CD27- B cells. At explant time, analysis of CD3 CD127lowCD25highFoxp3+ cell populations identified in GILs two clusters of CD4+CD8+ and three clusters of CD8 cells, which were expanded relative to PB or LNs. Conclusions: Observations regarding CD8 T-cell subpopulations in PB, LNs, and GILs support the conventional paradigm regarding their role as key effector cells mediating graft injury. The prominence of CD4+CD8+CD127lowCD25highFoxp3+ T cells and that of IgD-CD27- B cells among GILs have not previously been described. Expansion of circulating eosinophils around the time of rejection may implicate these cells in rejection mechanisms. Comparison of graft lymphocyte subpopulations with LNs or PB highlights mechanistically plausible differences that justify further efforts to elucidate their roles in graft injury and protection as a strategy to identify new candidate approaches to prevent rejection and promote tolerance.

Indexed as

Graft RejectionHeart TransplantationImmunosuppressive AgentsLeukocytesAnimalsGraft SurvivalMacaca fascicularisMaleTransplantation, HeterotopicImmunosuppressive Agentscynomolgus macaqueheart heterotopic allotransplantationintragraft lymphocytesleucocyte dynamicsT cells subpopulation

Identifiers

PMID41142830
PMCPMC12549273

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.